Global Broluzumab Biosimilars Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
LPI (LP Information)' newest research report, the “Broluzumab Biosimilars Industry Forecast” looks at past sales and reviews total world Broluzumab Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Broluzumab Biosimilars sales for 2023 through 2029. With Broluzumab Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Broluzumab Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Broluzumab Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Broluzumab Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Broluzumab Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Broluzumab Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Broluzumab Biosimilars.
The global Broluzumab Biosimilars market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Broluzumab Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Broluzumab Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Broluzumab Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Broluzumab Biosimilars players cover Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Broluzumab Biosimilars market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Broluzumab Biosimilars market?
What factors are driving Broluzumab Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Broluzumab Biosimilars market opportunities vary by end market size?
How does Broluzumab Biosimilars break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
LPI (LP Information)' newest research report, the “Broluzumab Biosimilars Industry Forecast” looks at past sales and reviews total world Broluzumab Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Broluzumab Biosimilars sales for 2023 through 2029. With Broluzumab Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Broluzumab Biosimilars industry.
This Insight Report provides a comprehensive analysis of the global Broluzumab Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Broluzumab Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Broluzumab Biosimilars market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Broluzumab Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Broluzumab Biosimilars.
The global Broluzumab Biosimilars market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Broluzumab Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Broluzumab Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Broluzumab Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Broluzumab Biosimilars players cover Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Broluzumab Biosimilars market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Beovu
- Vsiqq
- Others
- ARMD
- Kaposi Sarcoma
- Glioblastoma
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Genentech
- Roche
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
- Luye Pharmaceutical
- Henlius
What is the 10-year outlook for the global Broluzumab Biosimilars market?
What factors are driving Broluzumab Biosimilars market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Broluzumab Biosimilars market opportunities vary by end market size?
How does Broluzumab Biosimilars break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Broluzumab Biosimilars Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Broluzumab Biosimilars by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Broluzumab Biosimilars by Country/Region, 2018, 2022 & 2029
2.2 Broluzumab Biosimilars Segment by Type
2.2.1 Beovu
2.2.2 Vsiqq
2.2.3 Others
2.3 Broluzumab Biosimilars Sales by Type
2.3.1 Global Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
2.3.2 Global Broluzumab Biosimilars Revenue and Market Share by Type (2018-2023)
2.3.3 Global Broluzumab Biosimilars Sale Price by Type (2018-2023)
2.4 Broluzumab Biosimilars Segment by Application
2.4.1 ARMD
2.4.2 Kaposi Sarcoma
2.4.3 Glioblastoma
2.5 Broluzumab Biosimilars Sales by Application
2.5.1 Global Broluzumab Biosimilars Sale Market Share by Application (2018-2023)
2.5.2 Global Broluzumab Biosimilars Revenue and Market Share by Application (2018-2023)
2.5.3 Global Broluzumab Biosimilars Sale Price by Application (2018-2023)
3 GLOBAL BROLUZUMAB BIOSIMILARS BY COMPANY
3.1 Global Broluzumab Biosimilars Breakdown Data by Company
3.1.1 Global Broluzumab Biosimilars Annual Sales by Company (2018-2023)
3.1.2 Global Broluzumab Biosimilars Sales Market Share by Company (2018-2023)
3.2 Global Broluzumab Biosimilars Annual Revenue by Company (2018-2023)
3.2.1 Global Broluzumab Biosimilars Revenue by Company (2018-2023)
3.2.2 Global Broluzumab Biosimilars Revenue Market Share by Company (2018-2023)
3.3 Global Broluzumab Biosimilars Sale Price by Company
3.4 Key Manufacturers Broluzumab Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Broluzumab Biosimilars Product Location Distribution
3.4.2 Players Broluzumab Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BROLUZUMAB BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Broluzumab Biosimilars Market Size by Geographic Region (2018-2023)
4.1.1 Global Broluzumab Biosimilars Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Broluzumab Biosimilars Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Broluzumab Biosimilars Market Size by Country/Region (2018-2023)
4.2.1 Global Broluzumab Biosimilars Annual Sales by Country/Region (2018-2023)
4.2.2 Global Broluzumab Biosimilars Annual Revenue by Country/Region (2018-2023)
4.3 Americas Broluzumab Biosimilars Sales Growth
4.4 APAC Broluzumab Biosimilars Sales Growth
4.5 Europe Broluzumab Biosimilars Sales Growth
4.6 Middle East & Africa Broluzumab Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Broluzumab Biosimilars Sales by Country
5.1.1 Americas Broluzumab Biosimilars Sales by Country (2018-2023)
5.1.2 Americas Broluzumab Biosimilars Revenue by Country (2018-2023)
5.2 Americas Broluzumab Biosimilars Sales by Type
5.3 Americas Broluzumab Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Broluzumab Biosimilars Sales by Region
6.1.1 APAC Broluzumab Biosimilars Sales by Region (2018-2023)
6.1.2 APAC Broluzumab Biosimilars Revenue by Region (2018-2023)
6.2 APAC Broluzumab Biosimilars Sales by Type
6.3 APAC Broluzumab Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Broluzumab Biosimilars by Country
7.1.1 Europe Broluzumab Biosimilars Sales by Country (2018-2023)
7.1.2 Europe Broluzumab Biosimilars Revenue by Country (2018-2023)
7.2 Europe Broluzumab Biosimilars Sales by Type
7.3 Europe Broluzumab Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Broluzumab Biosimilars by Country
8.1.1 Middle East & Africa Broluzumab Biosimilars Sales by Country (2018-2023)
8.1.2 Middle East & Africa Broluzumab Biosimilars Revenue by Country (2018-2023)
8.2 Middle East & Africa Broluzumab Biosimilars Sales by Type
8.3 Middle East & Africa Broluzumab Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Broluzumab Biosimilars
10.3 Manufacturing Process Analysis of Broluzumab Biosimilars
10.4 Industry Chain Structure of Broluzumab Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Broluzumab Biosimilars Distributors
11.3 Broluzumab Biosimilars Customer
12 WORLD FORECAST REVIEW FOR BROLUZUMAB BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Broluzumab Biosimilars Market Size Forecast by Region
12.1.1 Global Broluzumab Biosimilars Forecast by Region (2024-2029)
12.1.2 Global Broluzumab Biosimilars Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Broluzumab Biosimilars Forecast by Type
12.7 Global Broluzumab Biosimilars Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Broluzumab Biosimilars Product Portfolios and Specifications
13.1.3 Novartis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Genentech
13.2.1 Genentech Company Information
13.2.2 Genentech Broluzumab Biosimilars Product Portfolios and Specifications
13.2.3 Genentech Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Genentech Main Business Overview
13.2.5 Genentech Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Broluzumab Biosimilars Product Portfolios and Specifications
13.3.3 Roche Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Broluzumab Biosimilars Product Portfolios and Specifications
13.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Sartorius
13.5.1 Sartorius Company Information
13.5.2 Sartorius Broluzumab Biosimilars Product Portfolios and Specifications
13.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sartorius Main Business Overview
13.5.5 Sartorius Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Broluzumab Biosimilars Product Portfolios and Specifications
13.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Bayer
13.7.1 Bayer Company Information
13.7.2 Bayer Broluzumab Biosimilars Product Portfolios and Specifications
13.7.3 Bayer Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Bayer Main Business Overview
13.7.5 Bayer Latest Developments
13.8 Amgen
13.8.1 Amgen Company Information
13.8.2 Amgen Broluzumab Biosimilars Product Portfolios and Specifications
13.8.3 Amgen Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen Main Business Overview
13.8.5 Amgen Latest Developments
13.9 PlantForm
13.9.1 PlantForm Company Information
13.9.2 PlantForm Broluzumab Biosimilars Product Portfolios and Specifications
13.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 PlantForm Main Business Overview
13.9.5 PlantForm Latest Developments
13.10 PharmaPraxis
13.10.1 PharmaPraxis Company Information
13.10.2 PharmaPraxis Broluzumab Biosimilars Product Portfolios and Specifications
13.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 PharmaPraxis Main Business Overview
13.10.5 PharmaPraxis Latest Developments
13.11 Samsung Bioepis
13.11.1 Samsung Bioepis Company Information
13.11.2 Samsung Bioepis Broluzumab Biosimilars Product Portfolios and Specifications
13.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Samsung Bioepis Main Business Overview
13.11.5 Samsung Bioepis Latest Developments
13.12 Centus
13.12.1 Centus Company Information
13.12.2 Centus Broluzumab Biosimilars Product Portfolios and Specifications
13.12.3 Centus Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Centus Main Business Overview
13.12.5 Centus Latest Developments
13.13 Cadila Pharmaceuticals
13.13.1 Cadila Pharmaceuticals Company Information
13.13.2 Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
13.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Cadila Pharmaceuticals Main Business Overview
13.13.5 Cadila Pharmaceuticals Latest Developments
13.14 Dr Reddy's
13.14.1 Dr Reddy's Company Information
13.14.2 Dr Reddy's Broluzumab Biosimilars Product Portfolios and Specifications
13.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Dr Reddy's Main Business Overview
13.14.5 Dr Reddy's Latest Developments
13.15 Aurobindo Pharma
13.15.1 Aurobindo Pharma Company Information
13.15.2 Aurobindo Pharma Broluzumab Biosimilars Product Portfolios and Specifications
13.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Aurobindo Pharma Main Business Overview
13.15.5 Aurobindo Pharma Latest Developments
13.16 Biocad
13.16.1 Biocad Company Information
13.16.2 Biocad Broluzumab Biosimilars Product Portfolios and Specifications
13.16.3 Biocad Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Biocad Main Business Overview
13.16.5 Biocad Latest Developments
13.17 MAbxience
13.17.1 MAbxience Company Information
13.17.2 MAbxience Broluzumab Biosimilars Product Portfolios and Specifications
13.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 MAbxience Main Business Overview
13.17.5 MAbxience Latest Developments
13.18 Hetero
13.18.1 Hetero Company Information
13.18.2 Hetero Broluzumab Biosimilars Product Portfolios and Specifications
13.18.3 Hetero Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Hetero Main Business Overview
13.18.5 Hetero Latest Developments
13.19 Biocon
13.19.1 Biocon Company Information
13.19.2 Biocon Broluzumab Biosimilars Product Portfolios and Specifications
13.19.3 Biocon Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Biocon Main Business Overview
13.19.5 Biocon Latest Developments
13.20 Kirin Biologics
13.20.1 Kirin Biologics Company Information
13.20.2 Kirin Biologics Broluzumab Biosimilars Product Portfolios and Specifications
13.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Kirin Biologics Main Business Overview
13.20.5 Kirin Biologics Latest Developments
13.21 Mylan
13.21.1 Mylan Company Information
13.21.2 Mylan Broluzumab Biosimilars Product Portfolios and Specifications
13.21.3 Mylan Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Mylan Main Business Overview
13.21.5 Mylan Latest Developments
13.22 BeiGene
13.22.1 BeiGene Company Information
13.22.2 BeiGene Broluzumab Biosimilars Product Portfolios and Specifications
13.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 BeiGene Main Business Overview
13.22.5 BeiGene Latest Developments
13.23 Innovent
13.23.1 Innovent Company Information
13.23.2 Innovent Broluzumab Biosimilars Product Portfolios and Specifications
13.23.3 Innovent Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Innovent Main Business Overview
13.23.5 Innovent Latest Developments
13.24 Qilu Pharmaceutical
13.24.1 Qilu Pharmaceutical Company Information
13.24.2 Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
13.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 Qilu Pharmaceutical Main Business Overview
13.24.5 Qilu Pharmaceutical Latest Developments
13.25 Hengrui Pharmaceuticals
13.25.1 Hengrui Pharmaceuticals Company Information
13.25.2 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
13.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 Hengrui Pharmaceuticals Main Business Overview
13.25.5 Hengrui Pharmaceuticals Latest Developments
13.26 Hisun Pharmaceutical
13.26.1 Hisun Pharmaceutical Company Information
13.26.2 Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
13.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 Hisun Pharmaceutical Main Business Overview
13.26.5 Hisun Pharmaceutical Latest Developments
13.27 TOT BIOPHARM
13.27.1 TOT BIOPHARM Company Information
13.27.2 TOT BIOPHARM Broluzumab Biosimilars Product Portfolios and Specifications
13.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.27.4 TOT BIOPHARM Main Business Overview
13.27.5 TOT BIOPHARM Latest Developments
13.28 Luye Pharmaceutical
13.28.1 Luye Pharmaceutical Company Information
13.28.2 Luye Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
13.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.28.4 Luye Pharmaceutical Main Business Overview
13.28.5 Luye Pharmaceutical Latest Developments
13.29 Henlius
13.29.1 Henlius Company Information
13.29.2 Henlius Broluzumab Biosimilars Product Portfolios and Specifications
13.29.3 Henlius Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.29.4 Henlius Main Business Overview
13.29.5 Henlius Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Broluzumab Biosimilars Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Broluzumab Biosimilars by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Broluzumab Biosimilars by Country/Region, 2018, 2022 & 2029
2.2 Broluzumab Biosimilars Segment by Type
2.2.1 Beovu
2.2.2 Vsiqq
2.2.3 Others
2.3 Broluzumab Biosimilars Sales by Type
2.3.1 Global Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
2.3.2 Global Broluzumab Biosimilars Revenue and Market Share by Type (2018-2023)
2.3.3 Global Broluzumab Biosimilars Sale Price by Type (2018-2023)
2.4 Broluzumab Biosimilars Segment by Application
2.4.1 ARMD
2.4.2 Kaposi Sarcoma
2.4.3 Glioblastoma
2.5 Broluzumab Biosimilars Sales by Application
2.5.1 Global Broluzumab Biosimilars Sale Market Share by Application (2018-2023)
2.5.2 Global Broluzumab Biosimilars Revenue and Market Share by Application (2018-2023)
2.5.3 Global Broluzumab Biosimilars Sale Price by Application (2018-2023)
3 GLOBAL BROLUZUMAB BIOSIMILARS BY COMPANY
3.1 Global Broluzumab Biosimilars Breakdown Data by Company
3.1.1 Global Broluzumab Biosimilars Annual Sales by Company (2018-2023)
3.1.2 Global Broluzumab Biosimilars Sales Market Share by Company (2018-2023)
3.2 Global Broluzumab Biosimilars Annual Revenue by Company (2018-2023)
3.2.1 Global Broluzumab Biosimilars Revenue by Company (2018-2023)
3.2.2 Global Broluzumab Biosimilars Revenue Market Share by Company (2018-2023)
3.3 Global Broluzumab Biosimilars Sale Price by Company
3.4 Key Manufacturers Broluzumab Biosimilars Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Broluzumab Biosimilars Product Location Distribution
3.4.2 Players Broluzumab Biosimilars Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BROLUZUMAB BIOSIMILARS BY GEOGRAPHIC REGION
4.1 World Historic Broluzumab Biosimilars Market Size by Geographic Region (2018-2023)
4.1.1 Global Broluzumab Biosimilars Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Broluzumab Biosimilars Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Broluzumab Biosimilars Market Size by Country/Region (2018-2023)
4.2.1 Global Broluzumab Biosimilars Annual Sales by Country/Region (2018-2023)
4.2.2 Global Broluzumab Biosimilars Annual Revenue by Country/Region (2018-2023)
4.3 Americas Broluzumab Biosimilars Sales Growth
4.4 APAC Broluzumab Biosimilars Sales Growth
4.5 Europe Broluzumab Biosimilars Sales Growth
4.6 Middle East & Africa Broluzumab Biosimilars Sales Growth
5 AMERICAS
5.1 Americas Broluzumab Biosimilars Sales by Country
5.1.1 Americas Broluzumab Biosimilars Sales by Country (2018-2023)
5.1.2 Americas Broluzumab Biosimilars Revenue by Country (2018-2023)
5.2 Americas Broluzumab Biosimilars Sales by Type
5.3 Americas Broluzumab Biosimilars Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Broluzumab Biosimilars Sales by Region
6.1.1 APAC Broluzumab Biosimilars Sales by Region (2018-2023)
6.1.2 APAC Broluzumab Biosimilars Revenue by Region (2018-2023)
6.2 APAC Broluzumab Biosimilars Sales by Type
6.3 APAC Broluzumab Biosimilars Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Broluzumab Biosimilars by Country
7.1.1 Europe Broluzumab Biosimilars Sales by Country (2018-2023)
7.1.2 Europe Broluzumab Biosimilars Revenue by Country (2018-2023)
7.2 Europe Broluzumab Biosimilars Sales by Type
7.3 Europe Broluzumab Biosimilars Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Broluzumab Biosimilars by Country
8.1.1 Middle East & Africa Broluzumab Biosimilars Sales by Country (2018-2023)
8.1.2 Middle East & Africa Broluzumab Biosimilars Revenue by Country (2018-2023)
8.2 Middle East & Africa Broluzumab Biosimilars Sales by Type
8.3 Middle East & Africa Broluzumab Biosimilars Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Broluzumab Biosimilars
10.3 Manufacturing Process Analysis of Broluzumab Biosimilars
10.4 Industry Chain Structure of Broluzumab Biosimilars
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Broluzumab Biosimilars Distributors
11.3 Broluzumab Biosimilars Customer
12 WORLD FORECAST REVIEW FOR BROLUZUMAB BIOSIMILARS BY GEOGRAPHIC REGION
12.1 Global Broluzumab Biosimilars Market Size Forecast by Region
12.1.1 Global Broluzumab Biosimilars Forecast by Region (2024-2029)
12.1.2 Global Broluzumab Biosimilars Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Broluzumab Biosimilars Forecast by Type
12.7 Global Broluzumab Biosimilars Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Broluzumab Biosimilars Product Portfolios and Specifications
13.1.3 Novartis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Genentech
13.2.1 Genentech Company Information
13.2.2 Genentech Broluzumab Biosimilars Product Portfolios and Specifications
13.2.3 Genentech Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Genentech Main Business Overview
13.2.5 Genentech Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Broluzumab Biosimilars Product Portfolios and Specifications
13.3.3 Roche Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Broluzumab Biosimilars Product Portfolios and Specifications
13.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Sartorius
13.5.1 Sartorius Company Information
13.5.2 Sartorius Broluzumab Biosimilars Product Portfolios and Specifications
13.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sartorius Main Business Overview
13.5.5 Sartorius Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Broluzumab Biosimilars Product Portfolios and Specifications
13.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Bayer
13.7.1 Bayer Company Information
13.7.2 Bayer Broluzumab Biosimilars Product Portfolios and Specifications
13.7.3 Bayer Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Bayer Main Business Overview
13.7.5 Bayer Latest Developments
13.8 Amgen
13.8.1 Amgen Company Information
13.8.2 Amgen Broluzumab Biosimilars Product Portfolios and Specifications
13.8.3 Amgen Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen Main Business Overview
13.8.5 Amgen Latest Developments
13.9 PlantForm
13.9.1 PlantForm Company Information
13.9.2 PlantForm Broluzumab Biosimilars Product Portfolios and Specifications
13.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 PlantForm Main Business Overview
13.9.5 PlantForm Latest Developments
13.10 PharmaPraxis
13.10.1 PharmaPraxis Company Information
13.10.2 PharmaPraxis Broluzumab Biosimilars Product Portfolios and Specifications
13.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 PharmaPraxis Main Business Overview
13.10.5 PharmaPraxis Latest Developments
13.11 Samsung Bioepis
13.11.1 Samsung Bioepis Company Information
13.11.2 Samsung Bioepis Broluzumab Biosimilars Product Portfolios and Specifications
13.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Samsung Bioepis Main Business Overview
13.11.5 Samsung Bioepis Latest Developments
13.12 Centus
13.12.1 Centus Company Information
13.12.2 Centus Broluzumab Biosimilars Product Portfolios and Specifications
13.12.3 Centus Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Centus Main Business Overview
13.12.5 Centus Latest Developments
13.13 Cadila Pharmaceuticals
13.13.1 Cadila Pharmaceuticals Company Information
13.13.2 Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
13.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Cadila Pharmaceuticals Main Business Overview
13.13.5 Cadila Pharmaceuticals Latest Developments
13.14 Dr Reddy's
13.14.1 Dr Reddy's Company Information
13.14.2 Dr Reddy's Broluzumab Biosimilars Product Portfolios and Specifications
13.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Dr Reddy's Main Business Overview
13.14.5 Dr Reddy's Latest Developments
13.15 Aurobindo Pharma
13.15.1 Aurobindo Pharma Company Information
13.15.2 Aurobindo Pharma Broluzumab Biosimilars Product Portfolios and Specifications
13.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Aurobindo Pharma Main Business Overview
13.15.5 Aurobindo Pharma Latest Developments
13.16 Biocad
13.16.1 Biocad Company Information
13.16.2 Biocad Broluzumab Biosimilars Product Portfolios and Specifications
13.16.3 Biocad Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Biocad Main Business Overview
13.16.5 Biocad Latest Developments
13.17 MAbxience
13.17.1 MAbxience Company Information
13.17.2 MAbxience Broluzumab Biosimilars Product Portfolios and Specifications
13.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 MAbxience Main Business Overview
13.17.5 MAbxience Latest Developments
13.18 Hetero
13.18.1 Hetero Company Information
13.18.2 Hetero Broluzumab Biosimilars Product Portfolios and Specifications
13.18.3 Hetero Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Hetero Main Business Overview
13.18.5 Hetero Latest Developments
13.19 Biocon
13.19.1 Biocon Company Information
13.19.2 Biocon Broluzumab Biosimilars Product Portfolios and Specifications
13.19.3 Biocon Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Biocon Main Business Overview
13.19.5 Biocon Latest Developments
13.20 Kirin Biologics
13.20.1 Kirin Biologics Company Information
13.20.2 Kirin Biologics Broluzumab Biosimilars Product Portfolios and Specifications
13.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Kirin Biologics Main Business Overview
13.20.5 Kirin Biologics Latest Developments
13.21 Mylan
13.21.1 Mylan Company Information
13.21.2 Mylan Broluzumab Biosimilars Product Portfolios and Specifications
13.21.3 Mylan Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Mylan Main Business Overview
13.21.5 Mylan Latest Developments
13.22 BeiGene
13.22.1 BeiGene Company Information
13.22.2 BeiGene Broluzumab Biosimilars Product Portfolios and Specifications
13.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 BeiGene Main Business Overview
13.22.5 BeiGene Latest Developments
13.23 Innovent
13.23.1 Innovent Company Information
13.23.2 Innovent Broluzumab Biosimilars Product Portfolios and Specifications
13.23.3 Innovent Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Innovent Main Business Overview
13.23.5 Innovent Latest Developments
13.24 Qilu Pharmaceutical
13.24.1 Qilu Pharmaceutical Company Information
13.24.2 Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
13.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 Qilu Pharmaceutical Main Business Overview
13.24.5 Qilu Pharmaceutical Latest Developments
13.25 Hengrui Pharmaceuticals
13.25.1 Hengrui Pharmaceuticals Company Information
13.25.2 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
13.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 Hengrui Pharmaceuticals Main Business Overview
13.25.5 Hengrui Pharmaceuticals Latest Developments
13.26 Hisun Pharmaceutical
13.26.1 Hisun Pharmaceutical Company Information
13.26.2 Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
13.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 Hisun Pharmaceutical Main Business Overview
13.26.5 Hisun Pharmaceutical Latest Developments
13.27 TOT BIOPHARM
13.27.1 TOT BIOPHARM Company Information
13.27.2 TOT BIOPHARM Broluzumab Biosimilars Product Portfolios and Specifications
13.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.27.4 TOT BIOPHARM Main Business Overview
13.27.5 TOT BIOPHARM Latest Developments
13.28 Luye Pharmaceutical
13.28.1 Luye Pharmaceutical Company Information
13.28.2 Luye Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
13.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.28.4 Luye Pharmaceutical Main Business Overview
13.28.5 Luye Pharmaceutical Latest Developments
13.29 Henlius
13.29.1 Henlius Company Information
13.29.2 Henlius Broluzumab Biosimilars Product Portfolios and Specifications
13.29.3 Henlius Broluzumab Biosimilars Sales, Revenue, Price and Gross Margin (2018-2023)
13.29.4 Henlius Main Business Overview
13.29.5 Henlius Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Broluzumab Biosimilars Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Broluzumab Biosimilars Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Beovu
Table 4. Major Players of Vsiqq
Table 5. Major Players of Others
Table 6. Global Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 7. Global Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Table 8. Global Broluzumab Biosimilars Revenue by Type (2018-2023) & ($ million)
Table 9. Global Broluzumab Biosimilars Revenue Market Share by Type (2018-2023)
Table 10. Global Broluzumab Biosimilars Sale Price by Type (2018-2023) & (K USD/Unit)
Table 11. Global Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 12. Global Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Table 13. Global Broluzumab Biosimilars Revenue by Application (2018-2023)
Table 14. Global Broluzumab Biosimilars Revenue Market Share by Application (2018-2023)
Table 15. Global Broluzumab Biosimilars Sale Price by Application (2018-2023) & (K USD/Unit)
Table 16. Global Broluzumab Biosimilars Sales by Company (2018-2023) & (K Units)
Table 17. Global Broluzumab Biosimilars Sales Market Share by Company (2018-2023)
Table 18. Global Broluzumab Biosimilars Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Broluzumab Biosimilars Revenue Market Share by Company (2018-2023)
Table 20. Global Broluzumab Biosimilars Sale Price by Company (2018-2023) & (K USD/Unit)
Table 21. Key Manufacturers Broluzumab Biosimilars Producing Area Distribution and Sales Area
Table 22. Players Broluzumab Biosimilars Products Offered
Table 23. Broluzumab Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Broluzumab Biosimilars Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Broluzumab Biosimilars Sales Market Share Geographic Region (2018-2023)
Table 28. Global Broluzumab Biosimilars Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Broluzumab Biosimilars Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Broluzumab Biosimilars Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Broluzumab Biosimilars Sales Market Share by Country/Region (2018-2023)
Table 32. Global Broluzumab Biosimilars Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Broluzumab Biosimilars Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Broluzumab Biosimilars Sales by Country (2018-2023) & (K Units)
Table 35. Americas Broluzumab Biosimilars Sales Market Share by Country (2018-2023)
Table 36. Americas Broluzumab Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Broluzumab Biosimilars Revenue Market Share by Country (2018-2023)
Table 38. Americas Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 39. Americas Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 40. APAC Broluzumab Biosimilars Sales by Region (2018-2023) & (K Units)
Table 41. APAC Broluzumab Biosimilars Sales Market Share by Region (2018-2023)
Table 42. APAC Broluzumab Biosimilars Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Broluzumab Biosimilars Revenue Market Share by Region (2018-2023)
Table 44. APAC Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 45. APAC Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 46. Europe Broluzumab Biosimilars Sales by Country (2018-2023) & (K Units)
Table 47. Europe Broluzumab Biosimilars Sales Market Share by Country (2018-2023)
Table 48. Europe Broluzumab Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Broluzumab Biosimilars Revenue Market Share by Country (2018-2023)
Table 50. Europe Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 51. Europe Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Broluzumab Biosimilars Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Broluzumab Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Broluzumab Biosimilars Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Broluzumab Biosimilars
Table 59. Key Market Challenges & Risks of Broluzumab Biosimilars
Table 60. Key Industry Trends of Broluzumab Biosimilars
Table 61. Broluzumab Biosimilars Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Broluzumab Biosimilars Distributors List
Table 64. Broluzumab Biosimilars Customer List
Table 65. Global Broluzumab Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Broluzumab Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Broluzumab Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Broluzumab Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Broluzumab Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Broluzumab Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Broluzumab Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Broluzumab Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Broluzumab Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Broluzumab Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Broluzumab Biosimilars Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Broluzumab Biosimilars Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Broluzumab Biosimilars Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Broluzumab Biosimilars Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Novartis Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 80. Novartis Broluzumab Biosimilars Product Portfolios and Specifications
Table 81. Novartis Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Genentech Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 85. Genentech Broluzumab Biosimilars Product Portfolios and Specifications
Table 86. Genentech Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 87. Genentech Main Business
Table 88. Genentech Latest Developments
Table 89. Roche Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 90. Roche Broluzumab Biosimilars Product Portfolios and Specifications
Table 91. Roche Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 92. Roche Main Business
Table 93. Roche Latest Developments
Table 94. Pfizer Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer Broluzumab Biosimilars Product Portfolios and Specifications
Table 96. Pfizer Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Sartorius Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 100. Sartorius Broluzumab Biosimilars Product Portfolios and Specifications
Table 101. Sartorius Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 102. Sartorius Main Business
Table 103. Sartorius Latest Developments
Table 104. Eli Lilly Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 105. Eli Lilly Broluzumab Biosimilars Product Portfolios and Specifications
Table 106. Eli Lilly Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 107. Eli Lilly Main Business
Table 108. Eli Lilly Latest Developments
Table 109. Bayer Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 110. Bayer Broluzumab Biosimilars Product Portfolios and Specifications
Table 111. Bayer Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 112. Bayer Main Business
Table 113. Bayer Latest Developments
Table 114. Amgen Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 115. Amgen Broluzumab Biosimilars Product Portfolios and Specifications
Table 116. Amgen Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 117. Amgen Main Business
Table 118. Amgen Latest Developments
Table 119. PlantForm Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 120. PlantForm Broluzumab Biosimilars Product Portfolios and Specifications
Table 121. PlantForm Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 122. PlantForm Main Business
Table 123. PlantForm Latest Developments
Table 124. PharmaPraxis Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 125. PharmaPraxis Broluzumab Biosimilars Product Portfolios and Specifications
Table 126. PharmaPraxis Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 127. PharmaPraxis Main Business
Table 128. PharmaPraxis Latest Developments
Table 129. Samsung Bioepis Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 130. Samsung Bioepis Broluzumab Biosimilars Product Portfolios and Specifications
Table 131. Samsung Bioepis Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 132. Samsung Bioepis Main Business
Table 133. Samsung Bioepis Latest Developments
Table 134. Centus Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 135. Centus Broluzumab Biosimilars Product Portfolios and Specifications
Table 136. Centus Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 137. Centus Main Business
Table 138. Centus Latest Developments
Table 139. Cadila Pharmaceuticals Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 140. Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
Table 141. Cadila Pharmaceuticals Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 142. Cadila Pharmaceuticals Main Business
Table 143. Cadila Pharmaceuticals Latest Developments
Table 144. Dr Reddy's Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 145. Dr Reddy's Broluzumab Biosimilars Product Portfolios and Specifications
Table 146. Dr Reddy's Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 147. Dr Reddy's Main Business
Table 148. Dr Reddy's Latest Developments
Table 149. Aurobindo Pharma Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 150. Aurobindo Pharma Broluzumab Biosimilars Product Portfolios and Specifications
Table 151. Aurobindo Pharma Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 152. Aurobindo Pharma Main Business
Table 153. Aurobindo Pharma Latest Developments
Table 154. Biocad Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 155. Biocad Broluzumab Biosimilars Product Portfolios and Specifications
Table 156. Biocad Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 157. Biocad Main Business
Table 158. Biocad Latest Developments
Table 159. MAbxience Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 160. MAbxience Broluzumab Biosimilars Product Portfolios and Specifications
Table 161. MAbxience Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 162. MAbxience Main Business
Table 163. MAbxience Latest Developments
Table 164. Hetero Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 165. Hetero Broluzumab Biosimilars Product Portfolios and Specifications
Table 166. Hetero Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 167. Hetero Main Business
Table 168. Hetero Latest Developments
Table 169. Biocon Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 170. Biocon Broluzumab Biosimilars Product Portfolios and Specifications
Table 171. Biocon Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 172. Biocon Main Business
Table 173. Biocon Latest Developments
Table 174. Kirin Biologics Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 175. Kirin Biologics Broluzumab Biosimilars Product Portfolios and Specifications
Table 176. Kirin Biologics Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 177. Kirin Biologics Main Business
Table 178. Kirin Biologics Latest Developments
Table 179. Mylan Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 180. Mylan Broluzumab Biosimilars Product Portfolios and Specifications
Table 181. Mylan Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 182. Mylan Main Business
Table 183. Mylan Latest Developments
Table 184. BeiGene Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 185. BeiGene Broluzumab Biosimilars Product Portfolios and Specifications
Table 186. BeiGene Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 187. BeiGene Main Business
Table 188. BeiGene Latest Developments
Table 189. Innovent Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 190. Innovent Broluzumab Biosimilars Product Portfolios and Specifications
Table 191. Innovent Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 192. Innovent Main Business
Table 193. Innovent Latest Developments
Table 194. Qilu Pharmaceutical Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 195. Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
Table 196. Qilu Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 197. Qilu Pharmaceutical Main Business
Table 198. Qilu Pharmaceutical Latest Developments
Table 199. Hengrui Pharmaceuticals Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 200. Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
Table 201. Hengrui Pharmaceuticals Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 202. Hengrui Pharmaceuticals Main Business
Table 203. Hengrui Pharmaceuticals Latest Developments
Table 204. Hisun Pharmaceutical Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 205. Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
Table 206. Hisun Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 207. Hisun Pharmaceutical Main Business
Table 208. Hisun Pharmaceutical Latest Developments
Table 209. TOT BIOPHARM Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 210. TOT BIOPHARM Broluzumab Biosimilars Product Portfolios and Specifications
Table 211. TOT BIOPHARM Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 212. TOT BIOPHARM Main Business
Table 213. TOT BIOPHARM Latest Developments
Table 214. Luye Pharmaceutical Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 215. Luye Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
Table 216. Luye Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 217. Luye Pharmaceutical Main Business
Table 218. Luye Pharmaceutical Latest Developments
Table 219. Henlius Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 220. Henlius Broluzumab Biosimilars Product Portfolios and Specifications
Table 221. Henlius Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 222. Henlius Main Business
Table 223. Henlius Latest Developments
Table 1. Broluzumab Biosimilars Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Broluzumab Biosimilars Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Beovu
Table 4. Major Players of Vsiqq
Table 5. Major Players of Others
Table 6. Global Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 7. Global Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Table 8. Global Broluzumab Biosimilars Revenue by Type (2018-2023) & ($ million)
Table 9. Global Broluzumab Biosimilars Revenue Market Share by Type (2018-2023)
Table 10. Global Broluzumab Biosimilars Sale Price by Type (2018-2023) & (K USD/Unit)
Table 11. Global Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 12. Global Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Table 13. Global Broluzumab Biosimilars Revenue by Application (2018-2023)
Table 14. Global Broluzumab Biosimilars Revenue Market Share by Application (2018-2023)
Table 15. Global Broluzumab Biosimilars Sale Price by Application (2018-2023) & (K USD/Unit)
Table 16. Global Broluzumab Biosimilars Sales by Company (2018-2023) & (K Units)
Table 17. Global Broluzumab Biosimilars Sales Market Share by Company (2018-2023)
Table 18. Global Broluzumab Biosimilars Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Broluzumab Biosimilars Revenue Market Share by Company (2018-2023)
Table 20. Global Broluzumab Biosimilars Sale Price by Company (2018-2023) & (K USD/Unit)
Table 21. Key Manufacturers Broluzumab Biosimilars Producing Area Distribution and Sales Area
Table 22. Players Broluzumab Biosimilars Products Offered
Table 23. Broluzumab Biosimilars Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Broluzumab Biosimilars Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Broluzumab Biosimilars Sales Market Share Geographic Region (2018-2023)
Table 28. Global Broluzumab Biosimilars Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Broluzumab Biosimilars Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Broluzumab Biosimilars Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Broluzumab Biosimilars Sales Market Share by Country/Region (2018-2023)
Table 32. Global Broluzumab Biosimilars Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Broluzumab Biosimilars Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Broluzumab Biosimilars Sales by Country (2018-2023) & (K Units)
Table 35. Americas Broluzumab Biosimilars Sales Market Share by Country (2018-2023)
Table 36. Americas Broluzumab Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Broluzumab Biosimilars Revenue Market Share by Country (2018-2023)
Table 38. Americas Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 39. Americas Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 40. APAC Broluzumab Biosimilars Sales by Region (2018-2023) & (K Units)
Table 41. APAC Broluzumab Biosimilars Sales Market Share by Region (2018-2023)
Table 42. APAC Broluzumab Biosimilars Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Broluzumab Biosimilars Revenue Market Share by Region (2018-2023)
Table 44. APAC Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 45. APAC Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 46. Europe Broluzumab Biosimilars Sales by Country (2018-2023) & (K Units)
Table 47. Europe Broluzumab Biosimilars Sales Market Share by Country (2018-2023)
Table 48. Europe Broluzumab Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Broluzumab Biosimilars Revenue Market Share by Country (2018-2023)
Table 50. Europe Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 51. Europe Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Broluzumab Biosimilars Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Broluzumab Biosimilars Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Broluzumab Biosimilars Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Broluzumab Biosimilars Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Broluzumab Biosimilars Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Broluzumab Biosimilars
Table 59. Key Market Challenges & Risks of Broluzumab Biosimilars
Table 60. Key Industry Trends of Broluzumab Biosimilars
Table 61. Broluzumab Biosimilars Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Broluzumab Biosimilars Distributors List
Table 64. Broluzumab Biosimilars Customer List
Table 65. Global Broluzumab Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Broluzumab Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Broluzumab Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Broluzumab Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Broluzumab Biosimilars Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Broluzumab Biosimilars Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Broluzumab Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Broluzumab Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Broluzumab Biosimilars Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Broluzumab Biosimilars Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Broluzumab Biosimilars Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Broluzumab Biosimilars Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Broluzumab Biosimilars Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Broluzumab Biosimilars Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Novartis Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 80. Novartis Broluzumab Biosimilars Product Portfolios and Specifications
Table 81. Novartis Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Genentech Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 85. Genentech Broluzumab Biosimilars Product Portfolios and Specifications
Table 86. Genentech Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 87. Genentech Main Business
Table 88. Genentech Latest Developments
Table 89. Roche Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 90. Roche Broluzumab Biosimilars Product Portfolios and Specifications
Table 91. Roche Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 92. Roche Main Business
Table 93. Roche Latest Developments
Table 94. Pfizer Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer Broluzumab Biosimilars Product Portfolios and Specifications
Table 96. Pfizer Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Sartorius Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 100. Sartorius Broluzumab Biosimilars Product Portfolios and Specifications
Table 101. Sartorius Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 102. Sartorius Main Business
Table 103. Sartorius Latest Developments
Table 104. Eli Lilly Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 105. Eli Lilly Broluzumab Biosimilars Product Portfolios and Specifications
Table 106. Eli Lilly Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 107. Eli Lilly Main Business
Table 108. Eli Lilly Latest Developments
Table 109. Bayer Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 110. Bayer Broluzumab Biosimilars Product Portfolios and Specifications
Table 111. Bayer Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 112. Bayer Main Business
Table 113. Bayer Latest Developments
Table 114. Amgen Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 115. Amgen Broluzumab Biosimilars Product Portfolios and Specifications
Table 116. Amgen Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 117. Amgen Main Business
Table 118. Amgen Latest Developments
Table 119. PlantForm Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 120. PlantForm Broluzumab Biosimilars Product Portfolios and Specifications
Table 121. PlantForm Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 122. PlantForm Main Business
Table 123. PlantForm Latest Developments
Table 124. PharmaPraxis Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 125. PharmaPraxis Broluzumab Biosimilars Product Portfolios and Specifications
Table 126. PharmaPraxis Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 127. PharmaPraxis Main Business
Table 128. PharmaPraxis Latest Developments
Table 129. Samsung Bioepis Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 130. Samsung Bioepis Broluzumab Biosimilars Product Portfolios and Specifications
Table 131. Samsung Bioepis Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 132. Samsung Bioepis Main Business
Table 133. Samsung Bioepis Latest Developments
Table 134. Centus Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 135. Centus Broluzumab Biosimilars Product Portfolios and Specifications
Table 136. Centus Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 137. Centus Main Business
Table 138. Centus Latest Developments
Table 139. Cadila Pharmaceuticals Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 140. Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
Table 141. Cadila Pharmaceuticals Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 142. Cadila Pharmaceuticals Main Business
Table 143. Cadila Pharmaceuticals Latest Developments
Table 144. Dr Reddy's Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 145. Dr Reddy's Broluzumab Biosimilars Product Portfolios and Specifications
Table 146. Dr Reddy's Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 147. Dr Reddy's Main Business
Table 148. Dr Reddy's Latest Developments
Table 149. Aurobindo Pharma Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 150. Aurobindo Pharma Broluzumab Biosimilars Product Portfolios and Specifications
Table 151. Aurobindo Pharma Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 152. Aurobindo Pharma Main Business
Table 153. Aurobindo Pharma Latest Developments
Table 154. Biocad Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 155. Biocad Broluzumab Biosimilars Product Portfolios and Specifications
Table 156. Biocad Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 157. Biocad Main Business
Table 158. Biocad Latest Developments
Table 159. MAbxience Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 160. MAbxience Broluzumab Biosimilars Product Portfolios and Specifications
Table 161. MAbxience Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 162. MAbxience Main Business
Table 163. MAbxience Latest Developments
Table 164. Hetero Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 165. Hetero Broluzumab Biosimilars Product Portfolios and Specifications
Table 166. Hetero Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 167. Hetero Main Business
Table 168. Hetero Latest Developments
Table 169. Biocon Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 170. Biocon Broluzumab Biosimilars Product Portfolios and Specifications
Table 171. Biocon Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 172. Biocon Main Business
Table 173. Biocon Latest Developments
Table 174. Kirin Biologics Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 175. Kirin Biologics Broluzumab Biosimilars Product Portfolios and Specifications
Table 176. Kirin Biologics Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 177. Kirin Biologics Main Business
Table 178. Kirin Biologics Latest Developments
Table 179. Mylan Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 180. Mylan Broluzumab Biosimilars Product Portfolios and Specifications
Table 181. Mylan Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 182. Mylan Main Business
Table 183. Mylan Latest Developments
Table 184. BeiGene Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 185. BeiGene Broluzumab Biosimilars Product Portfolios and Specifications
Table 186. BeiGene Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 187. BeiGene Main Business
Table 188. BeiGene Latest Developments
Table 189. Innovent Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 190. Innovent Broluzumab Biosimilars Product Portfolios and Specifications
Table 191. Innovent Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 192. Innovent Main Business
Table 193. Innovent Latest Developments
Table 194. Qilu Pharmaceutical Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 195. Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
Table 196. Qilu Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 197. Qilu Pharmaceutical Main Business
Table 198. Qilu Pharmaceutical Latest Developments
Table 199. Hengrui Pharmaceuticals Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 200. Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolios and Specifications
Table 201. Hengrui Pharmaceuticals Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 202. Hengrui Pharmaceuticals Main Business
Table 203. Hengrui Pharmaceuticals Latest Developments
Table 204. Hisun Pharmaceutical Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 205. Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
Table 206. Hisun Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 207. Hisun Pharmaceutical Main Business
Table 208. Hisun Pharmaceutical Latest Developments
Table 209. TOT BIOPHARM Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 210. TOT BIOPHARM Broluzumab Biosimilars Product Portfolios and Specifications
Table 211. TOT BIOPHARM Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 212. TOT BIOPHARM Main Business
Table 213. TOT BIOPHARM Latest Developments
Table 214. Luye Pharmaceutical Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 215. Luye Pharmaceutical Broluzumab Biosimilars Product Portfolios and Specifications
Table 216. Luye Pharmaceutical Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 217. Luye Pharmaceutical Main Business
Table 218. Luye Pharmaceutical Latest Developments
Table 219. Henlius Basic Information, Broluzumab Biosimilars Manufacturing Base, Sales Area and Its Competitors
Table 220. Henlius Broluzumab Biosimilars Product Portfolios and Specifications
Table 221. Henlius Broluzumab Biosimilars Sales (K Units), Revenue ($ Million), Price (K USD/Unit) and Gross Margin (2018-2023)
Table 222. Henlius Main Business
Table 223. Henlius Latest Developments
LIST OF FIGURES
Figure 1. Picture of Broluzumab Biosimilars
Figure 2. Broluzumab Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Broluzumab Biosimilars Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Broluzumab Biosimilars Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Broluzumab Biosimilars Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Beovu
Figure 10. Product Picture of Vsiqq
Figure 11. Product Picture of Others
Figure 12. Global Broluzumab Biosimilars Sales Market Share by Type in 2022
Figure 13. Global Broluzumab Biosimilars Revenue Market Share by Type (2018-2023)
Figure 14. Broluzumab Biosimilars Consumed in ARMD
Figure 15. Global Broluzumab Biosimilars Market: ARMD (2018-2023) & (K Units)
Figure 16. Broluzumab Biosimilars Consumed in Kaposi Sarcoma
Figure 17. Global Broluzumab Biosimilars Market: Kaposi Sarcoma (2018-2023) & (K Units)
Figure 18. Broluzumab Biosimilars Consumed in Glioblastoma
Figure 19. Global Broluzumab Biosimilars Market: Glioblastoma (2018-2023) & (K Units)
Figure 20. Global Broluzumab Biosimilars Sales Market Share by Application (2022)
Figure 21. Global Broluzumab Biosimilars Revenue Market Share by Application in 2022
Figure 22. Broluzumab Biosimilars Sales Market by Company in 2022 (K Units)
Figure 23. Global Broluzumab Biosimilars Sales Market Share by Company in 2022
Figure 24. Broluzumab Biosimilars Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Broluzumab Biosimilars Revenue Market Share by Company in 2022
Figure 26. Global Broluzumab Biosimilars Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Broluzumab Biosimilars Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 29. Americas Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 30. APAC Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 31. APAC Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 32. Europe Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 33. Europe Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 36. Americas Broluzumab Biosimilars Sales Market Share by Country in 2022
Figure 37. Americas Broluzumab Biosimilars Revenue Market Share by Country in 2022
Figure 38. Americas Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 39. Americas Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 40. United States Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Broluzumab Biosimilars Sales Market Share by Region in 2022
Figure 45. APAC Broluzumab Biosimilars Revenue Market Share by Regions in 2022
Figure 46. APAC Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 47. APAC Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 48. China Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Broluzumab Biosimilars Sales Market Share by Country in 2022
Figure 56. Europe Broluzumab Biosimilars Revenue Market Share by Country in 2022
Figure 57. Europe Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 58. Europe Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 59. Germany Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Broluzumab Biosimilars Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 68. Egypt Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Broluzumab Biosimilars in 2022
Figure 74. Manufacturing Process Analysis of Broluzumab Biosimilars
Figure 75. Industry Chain Structure of Broluzumab Biosimilars
Figure 76. Channels of Distribution
Figure 77. Global Broluzumab Biosimilars Sales Market Forecast by Region (2024-2029)
Figure 78. Global Broluzumab Biosimilars Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Broluzumab Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Broluzumab Biosimilars Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Broluzumab Biosimilars Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Broluzumab Biosimilars Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Broluzumab Biosimilars
Figure 2. Broluzumab Biosimilars Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Broluzumab Biosimilars Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Broluzumab Biosimilars Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Broluzumab Biosimilars Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Beovu
Figure 10. Product Picture of Vsiqq
Figure 11. Product Picture of Others
Figure 12. Global Broluzumab Biosimilars Sales Market Share by Type in 2022
Figure 13. Global Broluzumab Biosimilars Revenue Market Share by Type (2018-2023)
Figure 14. Broluzumab Biosimilars Consumed in ARMD
Figure 15. Global Broluzumab Biosimilars Market: ARMD (2018-2023) & (K Units)
Figure 16. Broluzumab Biosimilars Consumed in Kaposi Sarcoma
Figure 17. Global Broluzumab Biosimilars Market: Kaposi Sarcoma (2018-2023) & (K Units)
Figure 18. Broluzumab Biosimilars Consumed in Glioblastoma
Figure 19. Global Broluzumab Biosimilars Market: Glioblastoma (2018-2023) & (K Units)
Figure 20. Global Broluzumab Biosimilars Sales Market Share by Application (2022)
Figure 21. Global Broluzumab Biosimilars Revenue Market Share by Application in 2022
Figure 22. Broluzumab Biosimilars Sales Market by Company in 2022 (K Units)
Figure 23. Global Broluzumab Biosimilars Sales Market Share by Company in 2022
Figure 24. Broluzumab Biosimilars Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Broluzumab Biosimilars Revenue Market Share by Company in 2022
Figure 26. Global Broluzumab Biosimilars Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Broluzumab Biosimilars Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 29. Americas Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 30. APAC Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 31. APAC Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 32. Europe Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 33. Europe Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Broluzumab Biosimilars Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Broluzumab Biosimilars Revenue 2018-2023 ($ Millions)
Figure 36. Americas Broluzumab Biosimilars Sales Market Share by Country in 2022
Figure 37. Americas Broluzumab Biosimilars Revenue Market Share by Country in 2022
Figure 38. Americas Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 39. Americas Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 40. United States Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Broluzumab Biosimilars Sales Market Share by Region in 2022
Figure 45. APAC Broluzumab Biosimilars Revenue Market Share by Regions in 2022
Figure 46. APAC Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 47. APAC Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 48. China Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Broluzumab Biosimilars Sales Market Share by Country in 2022
Figure 56. Europe Broluzumab Biosimilars Revenue Market Share by Country in 2022
Figure 57. Europe Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 58. Europe Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 59. Germany Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Broluzumab Biosimilars Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Application (2018-2023)
Figure 68. Egypt Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Broluzumab Biosimilars Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Broluzumab Biosimilars in 2022
Figure 74. Manufacturing Process Analysis of Broluzumab Biosimilars
Figure 75. Industry Chain Structure of Broluzumab Biosimilars
Figure 76. Channels of Distribution
Figure 77. Global Broluzumab Biosimilars Sales Market Forecast by Region (2024-2029)
Figure 78. Global Broluzumab Biosimilars Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Broluzumab Biosimilars Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Broluzumab Biosimilars Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Broluzumab Biosimilars Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Broluzumab Biosimilars Revenue Market Share Forecast by Application (2024-2029)
